Bio-Rad Laboratories (BIO)
Supplies droplet digital PCR, clinical-laboratory systems, reagents, controls, and recurring consumables.
Something off on this page? Send us feedback.
Sells instruments, systems, reagents, assays, controls, and consumables through Life Science and Clinical Diagnostics. Revenue leans toward clinical diagnostics, while recurring products connect many instruments to laboratory workflows and Droplet Digital PCR anchors the clearest current platform expansion.
Operates through Life Science and Clinical Diagnostics. Life Science spans molecular biology, PCR and Droplet Digital PCR, protein analysis, chromatography, cell biology, and single-cell workflows; Clinical Diagnostics covers quality controls, blood typing, diabetes and hemoglobin testing, autoimmune and infectious-disease testing, and multiplex immunoassays.
Pairs installed instruments and systems with assays, reagents, media, controls, and other consumables across laboratory workflows. A global research, manufacturing, and sales network serves universities, research institutions, hospitals, biopharmaceutical companies, and clinical laboratories.
Depends on research funding and biopharma demand in Life Science, and on regulatory clearance, quality systems, laboratory adoption, and reimbursement in Clinical Diagnostics. Repeated acquisitions underpin the Droplet Digital PCR platform, while founder-family voting control shapes governance. Fair-value changes in the external Sartorius stake flow through reported earnings without making Sartorius an operating segment.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 7, 2026 | RBC Capital | Reiterate | Rating: —Target: $370 | Target: $390 |
| Aug 5, 2026 | RBC Capital | Reiterate | Rating: —Target: $320 | Target: $370 |
| May 25, 2026 | Wells Fargo | Target | Target: $290 | Target: $310 |
| May 14, 2026 | RBC Capital | Target | Target: $565 | Target: $320 |
| May 1, 2026 | Wells Fargo | Reiterate | Rating: —Target: $320 | Target: $290 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.62B · Total debt $1.20B · Total assets $10.25B · Shareholders' equity $7.17B
- Revenue
- $651.0M
- Operating income
- $72.6M
- Net income
- $371.4M
No dividends on record.
| Institutions | ≥ 73.32% | 19.60M shares | |
|---|---|---|---|
| 405 holders · as of Jun 30, 2026 | |||
| Insiders | 27.18% | 7.27M shares | |
| 3 holders · as of Oct 30, 2025 | |||
| Adds to | 100.50% | ||
26.74M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Institutional filings for BIO-B (19% of the company) are not on file here, so the institutional figure is a floor.
These groups come from separate filings that can overlap, so they add to 100.50%; nothing is left for Other.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Norman D. Schwartz1Insiderdirector, 10 percent owner, officer: Chairman & CEO | 12.08% | 449,019 | filed Oct 30, 2025 |
Alice N. Schwartz1Insider10 percent owner, other: Director Emeritus | 10.22% | 437,510 | filed Jul 18, 2025 |
First Eagle Investment Management, LLCInstitution | 9.75% | 2.61M A | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 6.35% | 1.70M A | as of Jun 30, 2026 |
666 Third Ave. - 9th Floor, New York, New York 10017Insider | 4.89% | 1.31M | filed Nov 14, 2024 |
- The filed share classes (COMMON) could not be matched to the company's, so no percentage.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 11, 2026 | Eva Anette Engelhardt | officer: EVP, President, CDG | −550 | $246.54 |
| Nov 6, 2025 | James Barry | officer: EVP, President, LSG | −700 | $306.18 |
- Danaher
Broad overlap across bioprocessing, life-science tools, and diagnostics
- Thermo Fisher Scientific
Extensive overlap in PCR, protein analysis, cell biology, and bioprocessing
- Waters
Overlaps in flow cytometry, molecular diagnostics, and clinical workflows
- Abbott
Competes in core-lab, molecular, and cardiometabolic diagnostics
- QIAGEN
Closest specialist overlap in digital PCR and molecular workflows
- QuidelOrtho
Focused overlap in clinical immunoassay, blood typing, and infectious testing
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Bio-Rad Laboratories | $378.47 | +0.30% | $10.16B | 45.7 | 36.7 | 3.9 | −0.1% |
| Danaher | $218.21 | +1.10% | $151.67B | 38.3 | 24.7 | 6.0 | +5.5% |
| Thermo Fisher Scientific | $658.32 | −0.07% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| Waters | $429.05 | +1.21% | $41.62B | 105.7 | 27.5 | 9.0 | +113.3% |
| Abbott | $104.29 | +1.27% | $178.18B | 33.1 | 18.0 | 3.8 | +13.0% |
| QIAGEN | $44.05 | −1.63% | $9.24B | 23.0 | 17.7 | 4.4 | +0.3% |
| QuidelOrtho | $10.97 | +1.01% | $740.6M | — | 13.0 | 0.3 | +2.8% |
| Median | 35.4 | 21.3 | 4.8 | +8.0% |